Literature DB >> 11064119

Production monitoring and purification of EBV encoded latent membrane protein 1 expressed and secreted by recombinant baculovirus infected insect cells.

P Meij1, M B Vervoort, C J Meijer, E Bloemena, J M Middeldorp.   

Abstract

Epstein-Barr virus (EBV) encoded latent membrane protein 1 (LMP1) is expressed in malignancies with latency type II and III and is an important transforming protein. To further study this protein LMP1 was expressed by and purified from recombinant baculovirus infected Sf9 cells. Expression levels of LMP1 in EBV transformed B cell lines and Sf9 cells were analyzed using a newly developed quantitative LMP1-capture ELISA. Highest expression was found in the cell line X50/7 (6.2 ng/10(7) cells), whereas expression levels of recombinant LMP1 (bLMP1) in Sf9 cells reached 506 ng/10(7) cells. Surprisingly bLMP1 could also be detected in the culture medium as a stable full-length protein. Highest expression in Sf9 cells (506 ng/10(7) cells) was observed at 48 h post infection and in the culture medium (1590 ng/ml) at 96 h post infection. Before purification bLMP1 was solubilised using 0.22 m octyl-beta-glucoside at pH 6.0. Purification of bLMP1 using Q-Sepharose FF yielded 10-80 times enriched bLMP1 fractions, indicating that Q-Sepharose can be used for pre-purification. A one-step monoclonal antibody based immunoaffinity chromatography yielded highly purified bLMP1. Although the overall yields (20 microg purified LMP1 from 100 ml culture supernatant) and protein concentrations were low, higher concentrations of >95% purified BLMP1 could be reached after freeze drying.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064119     DOI: 10.1016/s0166-0934(00)00233-0

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  6 in total

1.  Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia.

Authors:  Servi J C Stevens; Sandra A W M Verkuijlen; Bambang Hariwiyanto; Jajah Fachiroh; Dewi K Paramita; I Bing Tan; Sophia M Haryana; Jaap M Middeldorp
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

2.  Purified hexameric Epstein-Barr virus-encoded BARF1 protein for measuring anti-BARF1 antibody responses in nasopharyngeal carcinoma patients.

Authors:  E K Hoebe; S H Hutajulu; J van Beek; S J Stevens; D K Paramita; A E Greijer; J M Middeldorp
Journal:  Clin Vaccine Immunol       Date:  2010-12-01

3.  Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.

Authors:  J Fachiroh; D K Paramita; B Hariwiyanto; A Harijadi; H L Dahlia; S R Indrasari; H Kusumo; Y S Zeng; T Schouten; S Mubarika; J M Middeldorp
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

4.  Induction of therapeutic antibodies by vaccination against external loops of tumor-associated viral latent membrane protein.

Authors:  Catherine Delbende; Claudie Verwaerde; Alexandra Mougel; Denis Tranchand Bunel
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

5.  A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia.

Authors:  Jin Qiu; Katherine Cosmopoulos; Michiel Pegtel; Erik Hopmans; Paul Murray; Jaap Middeldorp; Michael Shapiro; David A Thorley-Lawson
Journal:  PLoS Pathog       Date:  2011-08-25       Impact factor: 6.823

6.  Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9.

Authors:  Cécile Keryer-Bibens; Catherine Pioche-Durieu; Cécile Villemant; Sylvie Souquère; Nozomu Nishi; Mitsuomi Hirashima; Jaap Middeldorp; Pierre Busson
Journal:  BMC Cancer       Date:  2006-12-08       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.